Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor

Life Sciences

Volumn 80, Issue 23, 2007, Pages 2108-2117

  Araico, A ^a   Terencio, M C ^a   Alcaraz, M J ^a   Dominguez J N ^b   Leon C ^b   Ferrandiz M L ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

5 LO; Analgesic activity; Angiogenesis; Anti inflammatory activity; Chalcone derivatives; COX 2

Indexed keywords

1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; 2,4 DICHLORO 4' N [N' (4' METHYLPHENYLSULPHONYL)URENYL]CHALCONE; ANTIINFLAMMATORY AGENT; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; DEXAMETHASONE; INDOMETACIN; L 752860; LEUKOTRIENE B4; LIPOXYGENASE; MYELOPEROXIDASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXUDATE; FEMALE; GRANULOMA; INFLAMMATION; MOUSE; NONHUMAN; PAIN; PAW EDEMA; RAT; WRITHING TEST;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CHALCONES; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; RATS; RATS, WISTAR;

ANIMALIA; MURINAE; RATTUS;

EID: 34248549516     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.03.017     Document Type: Article

References (72)

1. Abramson S.B., and Weissmann G. The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis and Rheumatism 32 (1989) 1-9
2. Alcaraz M.J., Vicente A.M., Araico A., Dominguez J.N., Terencio M.C., and Ferrándiz M.L. Role of nuclear factor-κB and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. British Journal of Pharmacology 142 (2004) 1191-1199
3. Alvaro-Gracia J.M. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology 43 (2004) 121-125
4. Amann R., Schuligoi R., Lanz I., and Peskar B.A. Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat. European Journal of Pharmacology 306 (1996) 89-91
5. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., and Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. Journal of Clinical Investigation 97 (1996) 2672-2679
6. Araico A., Terencio M.C., Alcaraz M.J., Dominguez J.N., León C., and Ferrándiz M.L. Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. Life Sciences 78 (2006) 2911-2918
7. Argentieri D.C., Ritchie D.M., Ferro M.P., Kirchner T., Wachter M.P., Anderson D.W., Rosenthale M.E., and Capetola R.J. Tepoxalin: a dual cyclo-oxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favourable gastrointestinal profile. Journal of Pharmacology and Experimental Therapeutics 271 (1994) 1399-1408
8. Ballou L.R., Botting R.M., Goorha S., Zhang J., and Vane J.R. Nociception in cyclooxygenase isozyme-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 10272-10276
9. Bannwarth B. Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?. Fundamental and Clinical Pharmacology 18 (2003) 125-130
10. Beiche F., Scheuerer S., Brune K., Geisslinger G., and Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Letters 390 (1996) 165-169
11. Bennett G., al-Rashed S., Hoult J.R., and Brain S.D. Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils. Pain 77 (1998) 315-322
12. Boileau C., Pelletier J.-P., Tardif G., Fahmi H., Laufer S., Lavigne M., and Martel-Pelletier J. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Annals of the Rheumatic Diseases 64 (2005) 891-898
13. Celotti F., and Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacology Research 43 (2001) 429-436
14. Charlier C., and Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. European Journal of Medicinal Chemistry 38 (2003) 645-659
15. Claria J., and Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Current Pharmaceutical Design 11 (2005) 3431-3447
16. Colville-Nash P.R., Alam C.A., Appleton I., Brown J.R., Seed M.P., and Willoughby D.A. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. Journal of Pharmacology and Experimental Therapeutics 274 (1995) 1463-1472
17. De Gaetano G., Donati M.B., and Cerletti C. Prevention of trombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends in Pharmacological Sciences 24 (2003) 245-252
18. De León E.J., Alcaraz M.J., Domínguez J.N., Charris J., and Terencio M.C. 1-(2,3,4-trimethoxyphenyl)-3-(3-(2-chloroquinolinyl))-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Inflammation Research 52 (2003) 246-257
19. De León E.J., Alcaraz M.J., Domínguez J.N., Charris J., and Terencio M.C. A new chlorolquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. Journal of Pharmacy and Pharmacology 55 (2003) 1313-1321
20. De Young L.M., Kheifets J.B., Ballaron S.J., and Young J.M. Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. Agents and Actions 26 (1989) 335-341
21. Domínguez J.N., León C., Rodrigues J., Gamboa de Domínguez N., Gut J., and Rosenthal P. Synthesis and evaluation of new antimalarial phenylurenyl chalcones derivatives. Journal of Medicinal Chemistry 48 (2005) 3654-3658
22. Edwards J.C.W., Sedgwick A.D., and Willoughby D.A. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. Journal of Pathology 134 (1981) 147-156
23. Farndale R.W., Buttle D.J., and Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochimica et Biophysica Acta 883 (1986) 173-177
24. Francischi J.N., Chaves C.T., Moura A.C., Lima A.S., Rocha O.A., Ferreira-Alves D.L., and Bakhle Y.S. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. British Journal of Pharmacology 137 (2002) 837-844
25. Funatsu T., Chono K., Hirata T., Keto Y., Kimoto A., and Sasamata M. Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats. European Journal of Pharmacology 554 (2007) 53-59
26. Griswold D.E., Marshall P., Martin L., Webb E.F., and Zabko-Potapovich B. Analgesic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents and Actions Supplement 32 (1991) 113-117
27. Haraguchi H., Ishikawa H., Mizutani K., Tamura Y., and Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorganic and Medicinal Chemistry 6 (1998) 339-347
28. He W., Pelletier J.P., Martel-Pelletier J., Laufer S., and Di Battista J.A. The synthesis of interleukin-1beta, tumour necrosis factor-α and interstitial collagenase (MMP-1) is eicosanoid dependent in human OA synovial membrane explants: interactions with anti-inflammatory cytokines. Journal of Rheumatology 29 (2002) 546-553
29. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Current Medicinal Chemistry 7 (2000) 1113-1120
30. Hsieh H.K., Lee T.H., Wang J.P., Wang J.J., and Lin C.N. Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharmaceutical Research 15 (1998) 39-46
31. Hsieh H.K., Tsao L.T., Wang J.P., and Lin C.N. Synthesis and anti-inflammatory effect of chalcones. Journal of Pharmacy and Pharmacology 52 (2000) 163-171
32. Huang Y.C., Guh J.H., Cheng Z.J., Chang Y.L., Hwang T.L., Lin C.N., and Teng C.M. Inhibitory effect of DCDC on lipopolysaccharide-induced nitric oxide synthesis in RAW 264.7 cells. Life Sciences 68 (2001) 2435-2447
33. Inagaki M., Tsuri T., Jyoyama H., Ono T., Yamada K., Kobayashi M., Hori Y., Arimura A., Yasui K., Ohno K., Kakudo S., Koizumi K., Suzuki R., Kawai S., Kato M., and Matsumoto S. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. Journal of Medicinal Chemistry 41 (2000) 1112-1123
34. Jackson J.R., Bolognese B., Mangar C.A., Hubbard W.C., Marshall C.A., and Winkler J.D. The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis. Biochimica et Biophysica Acta 1392 (1998) 145-152
35. Janusz J.M., Young P.A., Ridgeway J.M., Scherz M.W., Enzweiler K., Wu L.I., Gan L., Darolia R., Matthews R.S., Hennes D., Kellstein D.E., Green S.A., Tulich J.L., Rosario-Jansen T., Magrisso I.J., Wehmeyer K.R., Kuhlenbeck D.L., Eichhold T.H., Dobson R.L., Sirko S.P., and Farmer R.W. New cyclooxygenase-2/5-lipoxygenase inhibitors: 1. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe anti-inflammatory and analgesic agents: discovery and variation of the 5-keto substituent. Journal of Medicinal Chemistry 41 (1998) 1112-1123
36. Kankaanranta H., Moilanen E., and Vapaatalo H. Effects of non-steroidal anti-inflammatory drugs on polymorphonuclear leukocyte functions in vitro: focus on fenamates. Naunyn-Schmiedeberg's Archives of Pharmacology 350 (1994) 685-691
37. Kirchner T., Aparicio B., Argentieri D.C., Lau C.Y., and Ritchie D.M. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID induced gastrointestinal inflammation. Prostaglandins, Leukotrienes, and Essential Fatty Acids 56 (1997) 417-423
38. Kirchner T., Argentieri D.C., Barbone A.G., Singer M., Steber M., Ansell J., Beers S.A., Wachter M.P., Wu W., Malloy E., Stewart A., and Ritchie D.M. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Journal of Pharmacology and Experimental Therapeutics 282 (1997) 1094-1101
39. Kusuhara H., Matsuyuki H., and Okumoto T. Involvement of prostaglandins produced by cyclooxygenase-1 in murine visceronociception induced by phenylquinone. Prostaglandins & Other Lipid Mediators 55 (1998) 43-49
40. Leahy K.M., Koki A.T., and Masferrer J.L. Role of cyclooxygenases in angiogenesis. Current Medicinal Chemistry 7 (2000) 1163-1170
41. 4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225 (1984) 743-745
42. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., and Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. Journal of Biology and Chemistry 270 (1995) 14255-14258
43. Madan B., Batra S., and Ghosh B. 2'-hydroxychalcone inhibits nuclear factor-kappaB and blocks tumor necrosis factor-alpha and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Molecular Pharmacology 58 (2000) 526-534
44. Marcouiller P., Pelletier J.P., Guevremont M., Martel-Pelletier J., Ranger P., Laufer S., and Reboul P. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1 beta synthesis. Journal of Rheumatology 32 (2005) 704-712
45. Martel-Pelletier J., Lajeunesse D., Reboul P., and Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Annals of Rheumatic Diseases 62 (2003) 501-509
46. 4 in osteoarthritic chondrocytes: role of the transforming growth factor β and eicosanoids. Arthritis and Rheumatism 50 (2004) 3925-3933
47. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., and Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 3228-3232
48. Middleton E.J. Effect of plant flavonoids on immune and inflammatory cell function. Advances in Experimental Medicine and Biology 439 (1998) 175-182
49. Moreau M., Daminet S., Martel-Pelletier J., Fernandes J., and Pelletier J.P. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics 28 (2005) 81-86
50. Moroney M.A., Alcaraz M.J., Forder R.A., Carey F., and Hoult J.R.S. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. Journal of Pharmacy and Pharmacology 40 (1988) 787-792
51. Morrison B.W., Christensen S., Yuan W., Brown J., Amlani S., and Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clinical Therapeutics 21 (1999) 943-953
52. Mylari B.L., Carty T.J., Moore P.F., and Zembrowski W.J. 1,2-Dihydro-1-oxopyrrolo[3,2,1-kl]phenothiazine-2-carboxamides and congeners, dual cyclooxygenase/5-lipoxygenase inhibitors with anti-inflammatory activity. Journal of Medicinal Chemistry 33 (1990) 2019-2024
53. Nickerson-Nutter C.L., and Medvedeff E.D. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis and Rheumatism 39 (1996) 515-521
54. Otterness I.G., and Moore P.F. Carrageenan foot edema test. Methods in Enzymology 162 (1988) 320-327
55. Ospina L.F., Calle J., Arteaga L., Pinzón R., Alcaraz M.J., and Payá M. Inhibition of acute and chronic inflammatory responses by the hydroxybenzoquinonic derivative rapanone. Planta Medica 67 (2001) 791-795
56. Parente L., and Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochemical Pharmacology 65 (2003) 153-159
57. Pennanen N., Lapinjoki S., Palander A., Urtti A., and Monkkonen J. Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. International Journal of Immunopharmacology 17 (1995) 475-480
58. Posadas I., Terencio M.C., Guillén I., Ferrándiz M.L., Coloma J., Payá M., and Alcaraz M.J. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology 361 (2000) 98-106
59. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Archives Internationales de Pharmacodynamie et de Therapie 111 (1957) 409-419
60. Rioja I., Terencio M.C., Ubeda A., Molina P., Tarraga A., Gonzalez-Tejero A., and Alcaraz M.J. A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase. European Journal of Pharmacology 434 (2002) 177-185
61. Rojas J., Payá M., Devesa I., Domínguez J.N., and Ferrándiz M.L. Therapeutic administration of 3,4,5-trimethoxy-4′-fluorochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology 368 (2003) 225-233
62. Rojas J., Paya M., Dominguez J.N., and Ferrandiz M.L. ttCH, a new selective inhibitor of inducible nitric oxide synthase expression with antiarthritic properties. European Journal of Pharmacology 465 (2003) 183-189
63. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., and Isakson P. Pharmacological and biochemical demonstration of the role of cyclo-oxygenase 2 in inflammation and pain. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 12013-12017
64. Smith J.A. Neutrophils, host defense, and inflammation: a double-edged sword. Journal of Leukocyte Biology 56 (1994) 672-686
65. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 13313-13318
66. - secretion in stomach. Journal of Physiology and Pharmacology 57 (2006) 661-676
67. Taurog J.D., Argentieri D.C., and McReynolds R.A. Adjuvant arthritis. Methods in Enzymology 162 (1988) 339-355
68. Tries S., Neupert W., and Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflammation Research 51 (2002) 135-143
69. Walsh D.A., and Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Research 3 (2001) 147-153
70. Weiss S.J. Tissue destruction by neutrophils. New England Journal of Medicine 320 (1989) 365-376
71. Winder C.V., Lembke L.A., and Stephens M.D. Comparative bioassay of drugs in adjuvant-induced arthritis in rats: flufenamic acid, mefenamic acid, and phenylbutazone. Arthritis and Rheumatism 12 (1969) 472-482
72. 2 production. Journal of Pharmacology and Experimental Therapeutics 283 (1997) 1069-1075